A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of Orally Administered OPS-2071 for 12 Weeks in Subjects With Crohn's Disease Showing Symptoms of Active Inflammation Despite Ongoing Treatment
Latest Information Update: 03 Oct 2021
At a glance
- Drugs OPS 2071 (Primary)
- Indications Crohn's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 16 Jun 2020 Status changed from recruiting to discontinued.
- 07 Jun 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 07 Nov 2019 Status changed from not yet recruiting to recruiting.